慢性肝病患者肌肉减少症干预研究进展*

doi:10.3969/j.issn.1672-5069.2025.06.040

摘要/Abstract

摘要： 肌肉减少症是指肌肉质量和力量进行性下降的全身性疾病。肌少症与终末期慢性肝病患者的不良结局和预后相关。现有干预手段在传统营养补充和运动干预的基础上,更加深入到细胞和分子及其信号通路等靶点的水平上。本文综述总结了慢性肝病肌少症的干预研究进展,以期为肌少症的临床治疗提供更多的帮助。

关键词: 慢性肝病, 肌肉减少症, 干预

Abstract: Sarcopenia is a systemic entity in which muscle mass and strength progressively decline. Sarcopenia is associated with poor outcomes and prognosis in patients with chronic liver disease, particularly in those at the end-stage. On the basis of traditional nutritional supplementation and exercise intervention, the existing intervention are extending more to target therapy for signaling pathways. In this review, we summarized the progress of intervention for sarcopenia in patients with chronic liver disease, in order to provide more references for the clinical management of sarcopenia.

Key words: Chronic liver disease, Sarcopenia, Intervention

张思琪, 孔明, 段钟平. 慢性肝病患者肌肉减少症干预研究进展^*[J]. 实用肝脏病杂志, 2025, 28(6): 957-960.

Zhang Siqi, Kong Ming, Duan Zhongping. Intervention for sarcopenia in patients with chronic liver diseases[J]. Journal of Practical Hepatology, 2025, 28(6): 957-960.

参考文献

[1] Cruz-jentoft AJ, Sayer AA. Sarcopenia. Lancet, 2019, 393(10191): 2636-2646.
[2] Mazeaud S, Zupo R, Couret A, et al. Prevalence of sarcopenia in liver cirrhosis: A systematic review and meta-analysis. Clin Transl Gastroenterol, 2023, 14(7): e00584.
[3] Montano-loza AJ. Clinical relevance of sarcopenia in patients with cirrhosis. World J Gastroenterol, 2014, 20(25): 8061-8071.
[4] Duong N, Sadowski B, Rangnekar AS.The impact of frailty, sarcopenia, and malnutrition on liver transplant outcomes.Clin Liver Dis (Hoboken),2021, 17(4): 271-276.
[5] Plauth M, Bernal W, Dasarathy S, et al. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr, 2019, 38(2): 485-521.
[6] Tsien CD, Mccullough A J, Dasarathy S.Late evening snack: exploiting a period of anabolic opportunity in cirrhosis.J Gastroenterol Hepatol,2012, 27(3): 430-441.
[7] Guo YJ, Tian ZB, Jiang N, et al. Effects of late evening snack on cirrhotic patients: A systematic review and meta-analysis. Gastroenterol Res Pract, 2018, 2018: 9189062.
[8] Bear DE, Langan A, Dimidi E, et al. β-Hydroxy-β-methylbutyrate and its impact on skeletal muscle mass and physical function in clinical practice: A systematic review and meta-analysis.Am J Clin Nutr,2019, 109(4): 1119-1132.
[9] Bischoff SC, Ockenga J, Eshraghian A, et al. Practical guideline on obesity care in patients with gastrointestinal and liver diseases-Joint ESPEN/UEG guideline. Clin Nutr, 2023, 42(6): 987-1024.
[10] Ceglia L.Vitamin D and its role in skeletal muscle. Curr Opin Clin Nutr Metab Care, 2009, 12(6): 628-633.
[11] Okubo T, Atsukawa M, Tsubota A, et al. Effect of vitamin D supplementation on skeletal muscle volume and strength in patients with decompensated liver cirrhosis undergoing branched chain amino acids supplementation:A prospective, randomized, controlled pilot trial. Nutrients, 2021, 13(6): 1874.
[12] Llibre-nieto G, Lira A, Vergara M, et al. Micronutrient deficiencies in patients with decompensated liver cirrhosis. Nutrients, 2021, 13(4): 1249.
[13] Yang W,Wang X,Yu Z,et al.Low levels of serum zinc associate with malnutrition risk assessed by the royal free hospital-nutritional prioritizing tool in cirrhosis. Biol Trace Elem Res, 2022, 200(10): 4289-4296.
[14] Nishikawa H,Enomoto H,Yoh K,et al.Serum zinc concentration and sarcopenia:A close linkage in chronic liver diseases.J Clin Med,2019,8(3): 336.
[15] Aslan A,Beyaz S,Gok O,et al.The effect of ellagic acid on caspase-3/bcl-2/nrf-2/nf-kb/tnf-α /cox-2 gene expression product apoptosis pathway: A new approach for muscle damage therapy. Mol Biol Rep, 2020, 47(4): 2573-2582.
[16] Nakae Y, Hirasaka K, Goto J, et al. Subcutaneous injection, from birth, of epigallocatechin-3-gallate, a component of green tea, limits the onset of muscular dystrophy in mdx mice:A quantitative histological, immunohistochemical and electrophysiological study.Histochem Cell Biol, 2008, 129(4): 489-501.
[17] López-hortas L,Pérez-larrán P,González-muñoz M J,et al.Recent developments on the extraction and application of ursolic acid. A review. Food Res Int, 2018, 103: 130-149.
[18] Kunkel SD, Elmore CJ, Bongers KS, et al. Ursolic acid increases skeletal muscle and brown fat and decreases diet-induced obesity, glucose intolerance and fatty liver disease. PLoS One, 2012, 7(6): e39332.
[19] Casciola R, Leoni l, Cuffari B, et al. Creatine supplementation to improve sarcopenia in chronic liver disease: Facts and perspectives. Nutrients, 2023, 15(4): 863.
[20] Chilibeck PD,Kaviani M,Candow DG,et al. Effect of creatine supplementation during resistance training on lean tissue mass and muscular strength in older adults: a meta-analysis. Open Access J Sports Med, 2017, 8: 213-226.
[21] Byeon HR, Jang SY, Lee Y, et al. New strains of akkermansia muciniphila and faecalibacterium prausnitzii are effective for improving the muscle strength of mice with immobilization-induced muscular atrophy. J Med Food, 2022, 25(6): 565-575.
[22] Prokopidis K, Giannos P, Kirwan R, et al.Impact of probiotics on muscle mass, muscle strength and lean mass: A systematic review and meta-analysis of randomized controlled trials.J Cachexia Sarcopenia Muscle,2023,14(1): 30-44.
[23] Sano A, Inoue J, Kakazu E, et al. Association of omega-3 polyunsaturated ftty acids with sarcopenia in liver cirrhosis patients with hepatocellular carcinoma. J Clin Transl Hepatol, 2024, 12(7): 613-624.
[24] Bird JK,Troesch B,Warnke I,et al.The effect of long chain omega-3 polyunsaturated fatty acids on muscle mass and function in sarcopenia: A scoping systematic review and meta-analysis.Clin Nutr ESPEN,2021,46: 73-86.
[25] Aamann L, Dam G, Borre M, et al. Resistance training increases muscle strength and muscle size in patients with liver cirrhosis. Clin Gastroenterol Hepatol, 2020, 18(5): 1179-1187,e6.
[26] Zenith L, Meena N, Ramadi A, et al. Eight weeks of exercise training increases aerobic capacity and muscle mass and reduces fatigue in patients with cirrhosis. Clin Gastroenterol Hepatol, 2014, 12(11): 1920-1926.e1922.
[27] Williams FR, Berzigotti A, Lord JM, et al. Impact of exercise on physical frailty in patients with chronic liver disease. Aliment Pharmacol Ther, 2019, 50(9): 988-1000.
[28] Carey EJ, Lai JC, Sonnenday C,et al. A north american expert opinion statement on sarcopenia in liver transplantation. Hepatology, 2019,70(5): 1816-1829.
[29] Kumar A, Davuluri G, Silva RNE, et al. Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis. Hepatology, 2017, 65(6): 2045-2058.
[30] Rose CF. Ammonia-lowering strategies for the treatment of hepatic encephalopathy. Clin Pharmacol Ther, 2012, 92(3): 321-331.
[31] Butterworth RF. L-ornithine l-aspartate for the treatment of sarcopenia in chronic liver disease: The taming of a vicious cycle. Can J Gastroenterol Hepatol, 2019, 2019: 8182195.
[32] Chrysavgis L, Adamantou M,Angelousi A,et al.The association of testosterone with sarcopenia and frailty in chronic liver disease. Eur J Clin Invest, 2024, 54(2): e14108.
[33] Sinclair M, Grossmann M, Gow PJ, et al. Testosterone in men with advanced liver disease: abnormalities and implications. J Gastroenterol Hepatol, 2015, 30(2): 244-251.
[34] Sinclair M, Grossmann M, Hoermann R, et al. Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial. J Hepatol, 2016, 65(5): 906-913.
[35] Perrini S, Laviola L, Carreira MC, et al. The gh/igf1 axis and signaling pathways in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosis. J Endocrinol, 2010, 205(3): 201-210.
[36] Wallace JD, Abbott-johnson WJ, Crawford DH, et al. GH treatment in adults with chronic liver disease: A randomized, double-blind, placebo-controlled, cross-over study. J Clin Endocrinol Metab, 2002, 87(6): 2751-2759.
[37] Donaghy A, Ross R, Wicks C, et al. Growth hormone therapy in patients with cirrhosis: a pilot study of efficacy and safety. Gastroenterology, 1997, 113(5): 1617-1622.
[38] Rudman D, Sewell CW, Ansley JD. Deficiency of carnitine in cachectic cirrhotic patients. J Clin Invest, 1977, 60(3): 716-723.
[39] Ebadi M, Bhanji RA, Mazurak VC, et al. Sarcopenia in cirrhosis: from pathogenesis to interventions. J Gastroenterol, 2019, 54(10): 845-859.
[40] Hiramatsu A, Aikata H, Uchikawa S, et al. Levocarnitine use is associated with improvement in sarcopenia in patients with liver cirrhosis. Hepatol Commun, 2019, 3(3): 348-355.
[41] Sartiani L, Spinelli V, Laurino A, et al. Pharmacological perspectives in sarcopenia: a potential role for renin-angiotensin system blockers? Clin Cases Miner Bone Metab, 2015, 12(2): 135-138.
[42] Lin YL, Chen SY, Lai YH, et al. Angiotensin II receptor blockade is associated with preserved muscle strength in chronic hemodialysis patients. BMC Nephrol, 2019, 20(1): 54.
[43] Lee SJ, Lehar A, Meir JU, et al. Targeting myostatin/activin a protects against skeletal muscle and bone loss during spaceflight. Proc Natl Acad Sci U S A, 2020, 117(38): 23942-23951.
[44] Becker C, Lord SR, Studenski SA, et al. Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial. Lancet Diabetes Endocrinol, 2015, 3(12): 948-957.
[45] Rooks D, Praestgaard J, Hariry S, et al. Treatment of sarcopenia with bimagrumab: Results from a phase II, randomized, controlled, proof-of-concept study. J Am Geriatr Soc, 2017, 65(9): 1988-1995.
[46] Sakuma K,Hamada K,Yamaguchi A,et al.Current nutritional and pharmacological approaches for attenuating sarcopenia.Cells,2023,12(19): 2422.
[47] Bouchi R, Fukuda T, Takeuchi T, et al. Insulin treatment attenuates decline of muscle mass in Japanese patients with type 2 diabetes. Calcif Tissue Int, 2017, 101(1): 1-8.
[48] Ferrari U, Then C, Rottenkolber M, et al. Longitudinal association of type 2 diabetes and insulin therapy with muscle parameters in the kora-age study. Acta Diabetol, 2020, 57(9): 1057-1063.
[49] Jin H, Xie W, Hu P, et al. The role of melatonin in sarcopenia: Advances and application prospects. Exp Gerontol, 2021, 149: 111319.
[50] Amstrup AK, Sikjaer T, Pedersen SB, et al. Reduced fat mass and increased lean mass in response to 1 year of melatonin treatment in postmenopausal women: A randomized placebo-controlled trial. Clin Endocrinol (Oxf), 2016, 84(3): 342-347.
[51] Lo JH,U KP, Yiu T, et al. Sarcopenia: Current treatments and new regenerative therapeutic approaches. J Orthop Translat, 2020, 23: 38-52.
[52] Pourmohammadi-bejarpasi Z, Roushandeh AM, Saberi A, et al. Mesenchymal stem cells-derived mitochondria transplantation mitigates I/R-induced injury, abolishes I/R-induced apoptosis, and restores motor function in acute ischemia stroke rat model. Brain Res Bull, 2020, 165: 70-80.
[53] Mahindran E, Law JX, Ng MH, et al. Mesenchymal stem cell transplantation for the treatment of age-related musculoskeletal frailty. Int J Mol Sci, 2021, 22(19): 10542.
[54] Chen H, Xu C, Zhang F, et al. The gut microbiota attenuates muscle wasting by regulating energy metabolism in chemotherapy-induced malnutrition rats.Cancer Chemother Pharmacol, 2020, 85(6): 1049-1062.

慢性肝病患者肌肉减少症干预研究进展^*

Intervention for sarcopenia in patients with chronic liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	文雯, 白洁, 李用国. 肌肉减少性肥胖对慢性肝病患者预后的影响研究进展^*[J]. 实用肝脏病杂志, 2025, 28(4): 481-484.
[2]	朱亭亭, 陈逸云, 谢帆慈, 李正鑫. 无创评估肝纤维化逆转研究进展^*[J]. 实用肝脏病杂志, 2025, 28(2): 169-172.
[3]	朱帝文, 张媛, 鲍应军, 顾俊鹏, 孙丽华, 任伟新. 经颈静脉穿刺肝组织活检操作要点及并发症分析^*[J]. 实用肝脏病杂志, 2025, 28(2): 290-293.
[4]	黄嘉伟, 纪雅丽, 周玲, 陈金军. 代谢相关脂肪性肝病患者SAF评分和脂肪肝进展抑制算法应用研究^*[J]. 实用肝脏病杂志, 2025, 28(1): 48-51.
[5]	王文川, 梁阔鹏, 何蕊玲, 王继涛, 吉晓林, 刘成禹, 张宣哲, 张清格, 郭海军, 张健, 高华方, 郑少阳, 祁小龙, 刘登湘. 社区2型糖尿病合并NAFLD患病流行率调查^*[J]. 实用肝脏病杂志, 2024, 27(1): 40-43.
[6]	蔺宁, 孔明, 段钟平. 非酒精性脂肪性肝病营养干预研究进展^*[J]. 实用肝脏病杂志, 2024, 27(1): 151-154.
[7]	邱婉春, 毛小荣, 邓乐风, 龚燕华, 孙雪, 李俊峰. 肝硬化并发肌肉减少症发生因素及其对自发性细菌性腹膜炎发生的影响^*[J]. 实用肝脏病杂志, 2023, 26(5): 674-677.
[8]	崔坡, 董士铭, 南月敏. 慢性基础肝病对新型冠状病毒肺炎患者结局的影响^*[J]. 实用肝脏病杂志, 2022, 25(6): 905-908.
[9]	蔺宁, 孔明, 段钟平. 肝病肌肉减少症发病机制研究进展^*[J]. 实用肝脏病杂志, 2022, 25(2): 301-304.
[10]	毕再鸿, 韩白乙拉, 王炳元. 治疗慢性肝病的新药:辛伐他汀^*[J]. 实用肝脏病杂志, 2021, 24(4): 603-606.
[11]	宋叶雨(综述), 范建高(审校). 少肌性肥胖合并脂肪性肝病的诊断与治疗[J]. 实用肝脏病杂志, 2021, 24(1): 149-152.
[12]	孔明, 段钟平, 陈煜. 举足轻重,持续关注肝病营养问题[J]. 实用肝脏病杂志, 2020, 23(4): 459-461.
[13]	唐承薇. 慢性肝病与血小板减少：临床处理观念的转变[J]. 实用肝脏病杂志, 2019, 22(4): 457-458.
[14]	金娟, 朱守林, 高静, 袁春梅. 尊严疗法联合心理干预对终末期原发性肝癌患者负性情绪和生活质量的影响研究^*[J]. 实用肝脏病杂志, 2018, 21(5): 805-806.
[15]	李瑛, 孙波, 王新. 结构式团体心理干预在经肝动脉化疗栓塞术治疗的原发性肝癌患者应用效果研究[J]. 实用肝脏病杂志, 2018, 21(3): 477-478.